ILiAD Biotechnologies - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeILiAD Biotechnologies
ILiAD Biotechnologies logo

ILiAD Biotechnologies

0 followers

About ILiAD Biotechnologies

ILiAD Biotechnologies is a clinical-stage biotechnology company focused on preventing and treating diseases caused by Bordetella pertussis. Its lead candidate BPZE1 represents a next-generation pertussis vaccine developed for nasal vaccination and prevention of whooping cough, with multiple Phase 2 clinical trials completed. The company emphasizes public health impact through innovative vaccine solutions and global clinical development. Headquartered with operations spanning efforts in vaccine research and development, ILiAD Biotechnologies aims to reduce pertussis-related morbidity and mortality.

Recent News

No recent news for this company.

Recent Deals

Key Team Members

Luis Rios-Nogales, M.D., Ph.D., M.B.A.

Executive VP and Chief Development Officer

Keith Rubin, M.D.

Founder and Chief Executive Officer

Stephanie Noviello, M.D., M.P.H.

Chief Medical Officer

Amy Fix

Chief Regulatory Officer

Bill Steinkrauss

Chief Financial Officer

Key Facts

HQ Location

Seattle, United States

Founded

2012

Employees

11 - 50

Status

Private

Website

https://iliadbio.com